Streetwise Live! Presents Algernon Pharmaceuticals on 01/27/2022. Learn More

Sector Expert: Mara Goldstein

Cantor Fitzgerald

Image: Mara Goldstein

Mara Goldstein joined Cantor Fitzgerald & Co. from Thomson Reuters, where she served as director of research for Reuters Insight. Goldstein was initially responsible for the firm's healthcare research practice, and later assumed responsibility for all research activities and sectors. Prior to that, Goldstein was an executive director and senior pharmaceutical analyst at CIBC World Markets. At Cantor, Goldstein covers the biotechnology sector. Goldstein also worked at Alex Brown & Sons and CS First Boston. She holds a bachelor's degree in economics from Purdue University.

Recent Interviews

Panelists Select 19 Companies for the 2016 Small-Cap Biotech Watchlist (12/15/15)

In advance of the Biotech Showcase 2016, The Life Sciences Report has once again solicited top analysts to provide the names of innovative biotech companies that investors should keep an eye on in the upcoming year.

Watchlist Analysts Forecast Continued Blue Sky for Biotech Industry (1/29/15)

For the last two years the biotech sector has experienced market-beating gains, even taking into account the industry-wide hiccup in early 2014. Can this trend continue? The five analysts who selected names for The Life Sciences Report's 2015 Small-Cap Biotech Watchlist spend their days considering this question; it comes into play with every recommendation they make. The topic came up in various contexts during the Watchlist panel at the 2015 Biotech Showcase: Here are four factors investors should consider as they move into 2015.

The Small-Cap Biotech Watchlist 2015 Unwrapped: Who Are These Guys? And Why Are They Here? (1/27/15)

At the Biotech Showcase 2015 in San Francisco, five biotech analysts examined the burgeoning small-cap life sciences marketplace and found every reason to believe its good health would continue into 2015 and beyond. The experts also sent investors who attended the panel discussion of The Life Sciences Report's 2015 Small-Cap Biotech Watchlist home with a bundle of robust investment opportunities, including a few new names. Read on to see which companies made the list, and why.

Recent Quotes

"SNSS' SNS-062 may have utility as a BTK inhibitor in treated patients with C481S mutations due to its binding site."

— Mara Goldstein, Cantor Fitzgerald (5/2/17)
more >

"SNSS' BTK and PDK1 programs and a third compound represent upside."

— Mara Goldstein, Cantor Fitzgerald (3/10/16)
more >

"SNSS' pipeline compounds have the ability to expand share valuation."

— Mara Goldstein, Cantor Fitzgerald (7/30/15)
more >

"We believe that SNSS will file a new drug application for Qinprezo."

— Mara Goldstein, Cantor Fitzgerald (6/12/15)
more >

"SNSS will submit an NDA for Qinprezo for AML, later this year."

— Mara Goldstein, Cantor Fitzgerald (5/14/15)
more >

"We think SNSS's next inflection point will be confirmation of NDA filing in the U.S."

— Mara Goldstein, Cantor Fitzgerald (3/13/15)
more >

"There is opportunity for the FDA to accept a new drug application filing from SNSS."

The Life Sciences Report Interview with Mara Goldstein (1/27/15)
more >

"We believe the FDA will agree to review SNSS' NDA filing, resulting in a revalued share price."

— Mara Goldstein, Cantor Fitzgerald (1/6/15)
more >

Due to permission requirements, not all quotes are shown.